Lümfoomiks

Lümfoomiks is a term used to describe an integrative omics approach to studying lymphoid malignancies, particularly lymphomas. The concept combines data from genomics, transcriptomics, epigenomics, proteomics, and metabolomics, often at the single-cell level, to characterize disease biology and inform research and, potentially, clinical decision-making. The word is formed from lümfoom (lymphoma) and the suffix -iks, modeled on other omics disciplines such as genomics and proteomics.

Scope and aims include refining lymphoma classification beyond traditional histopathology, identifying molecular subtypes, and uncovering mechanisms of lymphomagenesis. Lümfoomiks also seeks biomarkers for prognosis and treatment response and aims to guide precision therapies by linking molecular profiles to therapeutic targets.

Methods commonly envisioned within lümfoomiks involve high-throughput sequencing, mass spectrometry-based proteomics, single-cell profiling, and imaging techniques, paired with computational data integration and machine learning to synthesize multidimensional datasets. Applications span disease subtyping, risk stratification, biomarker discovery, and the identification of novel therapeutic targets.

Current status and challenges: lümfoomiks remains largely a research concept rather than a standardized clinical framework. Progress is demonstrated in exploratory studies and pilot projects, but broader clinical translation requires standardized data generation, robust analytical pipelines, cross-cohort reproducibility, cost considerations, and careful ethical and regulatory oversight.

See also: lymphoma, genomics, proteomics, epigenomics, precision oncology, multi-omics.